Yorkshire Lung Screening Trial: Biomarker sub-study
Research type
Research Study
Full title
An observational cohort sub-study of the Yorkshire Lung Screening Trial (YLST) to investigate the potential of biomarkers to improve the efficacy of lung cancer screening.
IRAS ID
241104
Contact name
Phil Crosbie
Contact email
Sponsor organisation
University of Leeds
Clinicaltrials.gov Identifier
18-NW-0575, NW Greater Manchester West
Duration of Study in the UK
5 years, 2 months, 1 days
Research summary
A biomarker is a chemical or molecule than can be found in blood or other body fluids or tissues that is a sign of an abnormal condition or disease. The main aim of the YLST biomarker study is to see if testing blood can detect or help detect early stage lung cancer without the need for a CT scan. Just in case this is not possible we are also looking if blood biomarkers can provide additional information to the CT scans. One of the problems with lung cancer CT screening is that you detect lung nodules in which we are not sure if they are benign or cancerous. Therefore we are also looking to see if a blood biomarker can help us work out which are going to be cancerous and which are benign. We are also looking to see if blood biomarker checked at the time of the first CT scan can predict which patients will develop a lung cancer in the 2 year observation period after the first scan. Finally, we are also looking to see if the biomarker can detect other cancers in addition to early stage lung cancer.
REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
18/NW/0575
Date of REC Opinion
7 Aug 2018
REC opinion
Favourable Opinion